{"entity":{"id":"nct06014190","kind":"trial","name":"HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer","aka":[],"tldr":"A phase 2 trial of HS-20089 in ovarian cancer and endometrial cancer, run by Hansoh BioMedical R&D Company, now recruiting.","summary":"HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer is a phase 2 interventional study registered as NCT06014190 by Hansoh BioMedical R&D Company, with 460 participants planned, started 2023-12-18 and due to reach its primary completion in 2025-12-31. Interventions recorded: HS-20089. Conditions listed: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06014190","url":"https://clinicaltrials.gov/study/NCT06014190"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian","endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":["hs-20089"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06014190","phase":"2","setting":"A Phase 2 Study of HS-20089 for Injection in Patients With Recurrent or Metastatic Ovarian Cancer and Endometrial Cancer","sponsor":"Hansoh BioMedical R&D Company","enrolled":460,"outcomes":[]},"route":"/trials/nct06014190/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"hs-20089","kind":"drug","name":"HS-20089","route":"/drugs/hs-20089/"}]}}